Economy

This section presents an evaluation of the costs (for the patient or the community) of the treatment, and its possible profitability. All the data used for this evaluation are presented below.

Treatment costs

Anticipated market price of 1 capsule of Iron-Coli: 10 cent.

Bacterial treatment price per patient and per year: 110 euro.

Average cost of bloodletting treatment per patient and per year in France: 300 euro.

Money saved per patient and per year: 40 euro.
This does not take into account the costs of a missing half-day's work, or the costs and time of transport, etc. Thus, the collective benefit could be even higher.

Treatment profitability

France

Annual production costs: 3,3 millions euro.

Annual income: 7,5 millions euro.

Annual profits: 4,2 millions euro.

Europe

Annual production costs: 25 millions euro.

Annual income: 82 millions euro.

Annual profits: 57 millions euro.

Data

Cost of the lab' made capsule prototype: 3 cent.

Market price of current probiotic capsules: between 6 and 35 cent.
(http://www.dieti-natura.com/bacteries-lactiques-1104.html?gclid=CPnO9P6WuboCFWfLtAod-ScAsw)
(http://www.cocooncenter.com/Arkopharma-Azinc-Adultes-Probiotiques-30-Comprimes_9129.html?gclid=CIG-pp2ZuboCFe7HtAod3lYA0w)
(http://www.fleurancenature.fr/complexe-ferments-lactiques.html?origine=L1&mkwid=sMNlWLy44_dc&pcrid=25236698593&kword=probiotiques&match=e&plid=&ectrans=1&gclid=CPukz9WXuboCFWfLtAod-ScAsw&xts=480830&xtor=SEC-2-GOO-[]-[]-S-[probiotiques]&xtdt=23049191)

The relatively low market price of Iron-Coli capsule is due to the fact that it is easy to produce capsules with only one strand of bacteria. Moreover the patients will have to take 3 capsules each day.

In France, according to Dr. Françoise Courtois (General Secretary of European Federation of Associations of Patients with Haemochromatosis), bloodletting is charged around 40 euro, but costs in reality around 60 euro. The French public welfare system takes charge of all the costs. If a bacterial treatment enables to save money, it will be a collective benefit.

According to the presidents of patients' associations, the average number of bloodlettings per patient and per year is 5. Our treatment could theoretically diminish this number by 2.

According to the presidents of patients' associations, there are around 100 000 patients in France, and 750 000 in Europe.